Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cheniere Energy

This article emphasizes the importance of stock picking in today's market, where elevated valuations and sector rotations make it essential for generating returns. I've identified two dividend stocks that stand out due to their strong fundamentals and growth potential. These selections cater to income investors seeking stability. By focusing on unique opportunities, I aim to navigate the market effectively. These dividend picks combine reliable income with promising growth prospects for long-term success.

Wake Up, It's Time To Pick Stocks: Here Are 2 Dividend Stocks I Love

Investors bumped its shares higher following a decent, if unspectacular, earnings report.

Why Abbott Laboratories Stock Was a Winner on Wednesday

ABT delivers a strong underlying base business performance in the third quarter of 2024.

Abbott Stock Gains on Q3 Earnings Beat, Margins Expand

Abbott Laboratories (NYSE:ABT ) Q3 2024 Results Conference Call October 16, 2024 9:00 AM ET Company Participants Mike Comilla - Vice President, Investor Relations Robert Ford - Chairman and Chief Executive Officer Phil Boudreau - Executive Vice President, Finance and Chief Financial Officer Conference Call Participants Travis Steed - BofA Securities Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan David Roman - Goldman Sachs Joshua Jennings - TD Cowen Vijay Kumar - Evercore ISI Joanne Wuensch - Citi Matt Miksic - Barclays Danielle Antalffy - UBS Operator Good day, and thank you for standing by. Welcome to Abbott's Third Quarter 2024 Earnings Conference Call.

Abbott Laboratories (ABT) Q3 2024 Earnings Call Transcript

Abbott Laboratories (ABT) shares rose Wednesday, after the drug and healthcare products maker reported better-than-expected quarterly results and raised the midpoint of its profit outlook on strong demand for its medical devices.

Abbott Laboratories Raises Its Outlook on Strong Medical Device Sales

Morgan Stanley

U.S. Bancorp

This morning, we see a new print on international trade as well as further articulation on Q3 earnings, particularly in banking/finance and Big Pharma. Pre-market futures are slightly up at this hour: the Dow +22 points, the S&P 500 +1 and the Nasdaq +5 points.

Quarterly Earnings Reports Summary

Both Imports and Exports were deeper into the negative than expected. Meanwhile, MS, ABT and USB all beat of Q3 earnings.

Imports/Exports Lower; Morgan Stanley, Abbott Beat in Q3

I reiterate a “Strong Buy” rating for Abbott Laboratories with a fair value of $135 per share due to their strong R&D pipeline and robust financial performance. Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals, leading to raised full-year EPS guidance. Despite ongoing NEC baby formula lawsuits, the financial impact is marginal, representing only 0.02% of total revenue.

Abbott Q3: Strong Growth In Medical Device And Pharma

Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About Abbott (ABT) Q3 Earnings

U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 20 points on Wednesday.

US Stocks Mixed; Abbott Reports Better-Than-Expected Q3 Results

Abbott (ABT) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.20 per share. This compares to earnings of $1.14 per share a year ago.

Abbott (ABT) Q3 Earnings and Revenues Surpass Estimates

Abbott Laboratories on Wednesday reported better-than-expected third-quarter earnings and sales, boosted by strength in the company's medical-devices business.

Abbott Labs beats Q3 sales and earnings expectations, raises full-year outlook

Abbott Laboratories earnings slightly topped Q3 views, with medical devices leading organic sales growth. Abbott stock edged lower.

Abbott Labs Earnings Edge Past Q3 Views, Led By Medical Devices

Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for quarterly earnings on strong sales of its medical devices including its glucose-monitoring products.

Abbott slightly raises profit forecast on strong medical device sales

Sales of $10.6 billion driven by strong underlying base business performance Reported sales growth of 4.9 percent; organic sales growth for underlying base business of 8.2 percent1, led by double-digit growth in Medical Devices Continues to strengthen portfolio with steady cadence of new product approvals, reimbursement coverage, and clinical data ABBOTT PARK, Ill., Oct. 16, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept.

Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range

Abbott Laboratories ABT will release earnings results for its third quarter, before the opening bell on Wednesday, Oct. 16.

Abbott Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Equifax

SL Green Realty

Sporting a Zacks Rank #2 (Buy), here are three top-rated stocks that investors will want to consider as their Q3 results approach on Wednesday, October 16.

3 Top-Rated Stocks to Watch as Earnings Approach: ABT, EFX, SLG

Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Abbott (ABT) This Earnings Season?

ABT's Neuromodulation growth is expected to have been driven by strong demand in international markets for the Eterna rechargeable spinal cord stimulation device.

Abbott's Q3 Earnings Release Coming Up, EPD Business in Focus

Abbott Laboratories will announce its Q3 results on the morning of 16th October, with earnings and topline growth largely expected to be in line with the Q2 trend. A year ago, all of Abbott's divisions had generated double-digit topline growth, making the base effect quite challenging to overcome. We touch upon some of the important goings-on in Abbott's two largest divisions - Medical Devices and Diagnostics - which jointly account for two-thirds of group sales.

Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event

Abbott (NYSE: ABT) will report its Q3 2024 results on Wednesday, Oct 16. We expect the company to post revenue of $10.6 billion and earnings of $1.20 on a per share and adjusted basis, aligning with the street expectations.

Diabetes Products To Drive Abbott's Q3

Evaluate the expected performance of Abbott (ABT) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Abbott (ABT) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

Enrollment completed ahead of schedule in the global IDE for Abbott's Volt™ PFA System Global FOCALFLEX trial now underway for Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ Advisor™ HD Grid X Mapping Catheter, Sensor Enabled™, receives U.S. Food and Drug Administration clearance, begins commercial launch ABBOTT PARK, Ill., Oct. 10, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has achieved new major milestones to support the company's growing suite of pulsed field ablation (PFA) solutions in electrophysiology: early completion of enrollment in the VOLT-AF IDE Study supporting the Volt™ PFA System, and the launch of the FOCALFLEX trial to assess the company's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ (SE), which will be used in the treatment of patients with paroxysmal atrial fibrillation.

Abbott Advances Pulsed Field Ablation Clinical Studies and Launches New Technology to Support Advanced Cardiac Mapping

Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Abbott (ABT) Earnings Expected to Grow: Should You Buy?

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

News for Abbott Labs Stock (ABT)